Table 1.
Demographic Baseline Characteristics by Study Group
| Characteristic | Caspofungin (n = 144) | Combined Triazole (n = 146) | Fluconazole (n = 100) | Voriconazole (n = 46) |
|---|---|---|---|---|
| Age in years, median (range) | 10.0 (0.3–20.5) | 9.4 (0.3–20.7) | 8.7 (0.3–20.0) | 11.9 (2.2–20.7) |
| Sex (n, %) | ||||
| Male | 89 (61.8) | 90 (61.6) | 65 (65.0) | 25 (54.3) |
| Female | 55 (38.2) | 56 (38.4) | 35 (35.0) | 21 (45.7) |
| Race (n, %) | ||||
| White | 109 (75.7) | 97 (66.4) | 63 (63.0) | 34 (73.9) |
| Black | 11 (7.6) | 22 (15.1) | 13 (13.0) | 9 (19.6) |
| Asian | 9 (6.3) | 6 (4.1) | 5 (5.0) | 1 (2.2) |
| Other | 4 (2.8) | 2 (1.4) | 2 (2.0) | 0 (0) |
| Unknown | 11 (7.6) | 19 (13) | 17 (17.0) | 2 (4.3) |
| Ethnicity (n/N, %) | ||||
| Hispanic | 26/138 (18.8) | 26/133 (19.5) | 16/92 (17.4) | 10/41 (24.4) |
| ECOG performance score | ||||
| 0 (fully active) | 96 (66.7) | 103 (70.5) | 74 (74.0) | 29 (63.0) |
| 1 (restricted strenuous) | 38 (26.4) | 41 (28.1) | 24 (24.0) | 17 (37.0) |
| 2 (ambulatory) | 10 (6.9) | 2 (1.4) | 2 (2.0) | 0 (0) |
| Disease (n, %) | ||||
| Malignancy | 99 (68.8) | 106 (72.6) | 67 (67.0) | 39 (84.8) |
| ALL | 44 (30.6) | 47 (32.2) | 30 (30.0) | 17 (37.0) |
| AML/MDS | 30 (20.8) | 45 (30.8) | 29 (29.0) | 16 (34.8) |
| Other leukemiaa | 11 (7.6) | 8 (5.5) | 6 (6.0) | 2 (4.3) |
| Other malignancyb | 14 (9.7) | 6 (4.1) | 2 (2.0) | 4 (8.7) |
| Nonmalignancy | 45 (31.2) | 40 (27.4) | 33 (33.0) | 7 (15.2) |
| Primary immunodeficiency | 14 (9.7) | 10 (6.8) | 7 (7.0) | 3 (6.5) |
| Bone marrow failure | 10 (6.9) | 12 (8.2) | 8 (8.0) | 4 (8.7) |
| Hemoglobinopathy | 10 (6.9) | 8 (5.5) | 8 (8.0) | 0 (0) |
| Metabolic syndrome | 11 (7.6) | 9 (6.2) | 9 (9.0) | 0 (0) |
| Missing | 0 (0) | 1 (0.7) | 1 (1.0) | 0 (0) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; JMML, juvenile myelomonocytic leukemia.
aIncludes CML, JMML, leukemia not-otherwise-specified, and T-cell large granular lymphocytic leukemia.
bIncludes Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors.